Home Page of the DPNA Website Learn about the Drug Prevention Network of the Americas, its history, principles, members, supporters, and board Looking for information about drug prevention?  Check out our web page links, books, presentations, position papers, and brochures Want to connect with national, regional or international drug prevention sites?  Visit our extensive Links section. Keep up with the latest drug prevention news and events. Ready to become a part of the Drug Prevention Network of the Americas?  Sign up on line.

WWW DPNA News and Updates
Drug Research
Drug Effects
Drug Information
Drug Trends
Best Practices
Drug Legalization
Drug Policy
Books and Guides
Funding Sources

Cannabis MS drug seeks approval

The Telegraph UK  06/09/2006

The first medicinal product based on cannabis was filed for approval in Britain yesterday, and could be widely available in a year's time.

Sativex, based on cannabis extract, is aimed at multiple sclerosis sufferers and is intended to treat the muscle stiffness associated with the condition.

The drug has been developed by GW Pharma, which is growing 11 acres of cannabis under glass at a secret location somewhere in Britain .

Some patients already use Sativex, which is imported from Canada where it is already approved, but British approval would make it far more widely available. At present most sufferers pay around 4 a day for the drug.

A spokesman for the MS Society said a "very significant number" of Britain 's 85,000 sufferers could benefit from using the drug, which at present is not available to many. "

People with MS are sourcing raw cannabis of whatever quality from goodness knows where and running goodness knows what risks," he said. "It is important that we do see properly tested, effective, cannabis-based drugs."

The drug has already been filed for approval once, but British regulators said they required more information.

Yesterday, Stephen Wright, of GW Pharma, said he was confident in the new data the company had obtained.

''We have a sizeable body of positive clinical data to support the efficacy and safety of Sativex in MS spasticity," he said. He believed that the drug would be widely available within 12 to 15 months.